PT95329A - Novos isolados de hcv - Google Patents

Novos isolados de hcv

Info

Publication number
PT95329A
PT95329A PT199095329A PT9532990A PT95329A PT 95329 A PT95329 A PT 95329A PT 199095329 A PT199095329 A PT 199095329A PT 9532990 A PT9532990 A PT 9532990A PT 95329 A PT95329 A PT 95329A
Authority
PT
Portugal
Prior art keywords
new
hcv
isolated hcv
new isolated
hcv1
Prior art date
Application number
PT199095329A
Other languages
English (en)
Other versions
PT95329B (pt
Inventor
J. Weiner Amy
Miyamura Tatsuo
Saito Izumu
Houghton Michael
Han Jang
A. Kolberg Janice
Cha Tai-An
Duncan Irvine Bruce
Original Assignee
Chiron Corporation
Akira Oya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27020120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT95329(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corporation, Akira Oya filed Critical Chiron Corporation
Publication of PT95329A publication Critical patent/PT95329A/pt
Publication of PT95329B publication Critical patent/PT95329B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Laminated Bodies (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT95329A 1989-09-15 1990-09-17 Novos isolados de hcv PT95329B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40804589A 1989-09-15 1989-09-15
US45614289A 1989-12-21 1989-12-21

Publications (2)

Publication Number Publication Date
PT95329A true PT95329A (pt) 1991-08-14
PT95329B PT95329B (pt) 1998-04-30

Family

ID=27020120

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95329A PT95329B (pt) 1989-09-15 1990-09-17 Novos isolados de hcv

Country Status (11)

Country Link
EP (2) EP0419182B2 (pt)
JP (3) JP3156200B2 (pt)
AT (1) ATE188998T1 (pt)
CA (1) CA2065287C (pt)
DE (1) DE69033425T3 (pt)
DK (1) DK0419182T4 (pt)
ES (1) ES2141081T5 (pt)
GR (1) GR3033100T3 (pt)
IE (2) IE903363A1 (pt)
PT (1) PT95329B (pt)
WO (1) WO1991004262A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4040339C2 (de) 1989-12-18 1999-07-08 Wellcome Found Virales Agens
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
AU7675491A (en) * 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
JP3050395B2 (ja) * 1990-06-12 2000-06-12 国立感染症研究所長 Ｃ型肝炎ウイルス抗原ポリペプチド、その産生方法および抗体の検出方法
US5747339A (en) 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
ATE150086T1 (de) * 1990-07-11 1997-03-15 Shionogi & Co Cdns-sequenz und detektion des hepatitis c-virus
WO1992001714A1 (fr) * 1990-07-24 1992-02-06 Yamanouchi Pharmaceutical Co., Ltd. Antigene du virus de l'hepatite non a, non b
DK0770679T4 (da) * 1990-11-03 2010-05-10 Siemens Healthcare Diagnostics HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
EP0485209A1 (en) * 1990-11-08 1992-05-13 Immuno Japan Inc. Non A, non B hepatitis virus related antigen, antibody detection systems, polynucleotides and polypeptides
EP0516859A1 (en) * 1990-11-29 1992-12-09 Toray Industries, Inc. Non-a non-b hepatitis virus antigen protein
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
CA2065690A1 (en) * 1991-04-10 1992-10-11 Hiroaki Okamoto Non-a, non-b hepatitis related antigens, detection systems, polynucleotides and polypeptides
BR9206131A (pt) * 1991-06-10 1995-05-02 Lucky Ltd Hepatite C: diagnóstico e vacinas
KR0185426B1 (ko) * 1991-06-24 1999-04-01 로버트 피. 블랙버언 씨형 간염 바이러스 폴리펩티드
DK0529493T3 (da) * 1991-08-27 1998-08-24 Hoffmann La Roche Fremgangsmåder og reagenser til hepatitis C-detektion
DK0608261T3 (da) * 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
WO1993006247A1 (en) * 1991-09-16 1993-04-01 Abbott Laboratories Hepatitis c assay
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
US6433159B1 (en) 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US6762024B2 (en) 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
DE69526973T3 (de) 1994-10-21 2010-01-07 Innogenetics N.V. Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel
EP1178116A1 (en) * 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
CN100400101C (zh) * 2000-08-17 2008-07-09 特里帕普股份公司 包含病毒唑的疫苗及其使用方法
JP2002125688A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｃ型肝炎ウイルスの高感度検出のためのオリゴヌクレオチドおよび検出法
DE10112748A1 (de) * 2001-03-14 2002-09-19 Transmit Technologietransfer Erfindung betreffend HCV-Erkrankungen
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
EP1537418A2 (en) * 2002-09-13 2005-06-08 Intercell AG Method for isolating hepatitis c virus peptides
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
JP5138230B2 (ja) 2004-01-07 2013-02-06 サード・ウェーブ・テクノロジーズ・インク Ｃ型肝炎ウイルスの遺伝子型の決定方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US4870026A (en) * 1982-09-16 1989-09-26 The General Hospital Corporation Non-A, non-B. hepatitis, virus, methods of identification purification, characterization, diagnosis and immunization
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
JPH01124387A (ja) * 1987-11-10 1989-05-17 Mitsubishi Kasei Corp 非ａ非ｂ型肝炎特異抗原をコードするｄｎａを有する発現ベクター、形質転換体および該抗原の産生方法
US5032511A (en) * 1987-03-31 1991-07-16 Mitsubishi Kasei Corporation DNA fragments coding for antigens specific to non-A non-B hepatitis, expression vectors containing said DNA fragments, transformants and process for producing said antigens
JP2590885B2 (ja) * 1987-03-31 1997-03-12 三菱化学株式会社 Ｄｎａ断片
CA1339351C (en) 1987-10-15 1997-08-26 Michael S. Urdea Nucleic acid multimers and amplified nucleic acid hybridization assays using same
WO1989004669A1 (en) * 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
JP2500880Y2 (ja) * 1988-05-02 1996-06-12 カシオ計算機株式会社 液晶表示装置
HUT54896A (en) * 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
JPH0330676A (ja) * 1989-06-28 1991-02-08 Sanwa Kagaku Kenkyusho Co Ltd 非ａ非ｂ型肝炎ウイルスのｄｎａ、そのクローン及びこれらの調製法
EP0416725A3 (en) * 1989-07-14 1991-03-20 Chugai Seiyaku Kabushiki Kaisha Blood-borne non-a, non-b hepatitis specific protein, dna encoding it, and process for its production

Also Published As

Publication number Publication date
EP0419182B2 (en) 2009-07-22
DK0419182T4 (da) 2009-11-23
CA2065287A1 (en) 1991-03-16
EP0939128A3 (en) 2004-06-09
DK0419182T3 (da) 2000-04-17
PT95329B (pt) 1998-04-30
JPH05506773A (ja) 1993-10-07
DE69033425T2 (de) 2000-06-08
ES2141081T3 (es) 2000-03-16
JP3156200B2 (ja) 2001-04-16
IE20020123A1 (en) 2003-05-28
EP0939128A2 (en) 1999-09-01
WO1991004262A1 (en) 1991-04-04
EP0419182B1 (en) 2000-01-19
JP2005143512A (ja) 2005-06-09
CA2065287C (en) 1999-12-21
IE903363A1 (en) 1991-04-10
DE69033425D1 (de) 2000-02-24
EP0419182A1 (en) 1991-03-27
JPH09187285A (ja) 1997-07-22
ATE188998T1 (de) 2000-02-15
DE69033425T3 (de) 2010-02-18
ES2141081T5 (es) 2009-12-11
GR3033100T3 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
DE69033425D1 (de) HCV-Isolat J-1
HUT65930A (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
DK0770679T3 (da) HCV-specifikke peptider, præparater indeholdende dem og anvendelse deraf
ES2029171A6 (es) Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
DE68927025D1 (de) HIV-2-Virusvarianten
ATE309367T1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
ATE119545T1 (de) Felincalicivirus-capsid-protein und nukleotidsequenz.
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
ATE120800T1 (de) Antigen-protein der sporozoit- und hepatischen phase von p. falciparum.
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
FI981381L (fi) Menetelmä HCV-polypeptidien valmistamiseksi
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910208

FG3A Patent granted, date of granting

Effective date: 19980123

PD4A Change of proprietorship

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US

Effective date: 20080215

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130123